NASDAQ: GRIGri Bio Inc Stock
$5.79-0.26 (-4.3%)
Updated May 26, 2023
GRI Price
$5.79
Fair Value Price
N/A
Market Cap
$16.90M
52 Week Low
$5.49
52 Week High
$36.90
P/E
-0.34x
P/B
545.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
66.65
Operating Cash Flow
-$7M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GRI Overview
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GRI is poor value based on its book value relative to its share price (545.19x), compared to the US Biotechnology industry average (5.18x)
P/B vs Industry Valuation
GRI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GRI due diligence checks available for Premium users.
Be the first to know about important GRI news, forecast changes, insider trades & much more!
GRI News
Valuation
GRI fair value
Fair Value of GRI stock based on Discounted Cash Flow (DCF)
Price
$5.79
Fair Value
$0.77
Overvalued by
649.26%
GRI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.34x
Industry
11.86x
Market
54.23x
GRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
545.19x
Industry
5.18x
GRI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRI's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.4M
Profit Margin
0%
GRI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.1M
Liabilities
$2.1M
Debt to equity
66.65
GRI's short-term assets ($2.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRI's short-term assets ($2.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
$0.0
Financing
$0.0
GRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRI vs Biotech Stocks
Gri Bio Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.